Targeting thapsigargin towards tumors

Søren Brøgger Christensen, Thi Quynh Nhu Doan, Eleonora Sandholdt Paulsen, Pankaj Sehgal, Jesper Vuust Møller, Poul Nissen, Samuel R. Denmeade, John T. Isaacs, Craig A Dionne

    81 Citations (Scopus)

    Abstract

    The skin irritating principle from Thapsia garganica was isolated, named thapsigargin and the structure elucidated. By inhibiting the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) thapsigargin provokes apoptosis in almost all cells. By conjugating thapsigargin to peptides, which are only substrates for either prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA) prodrugs were created, which selectively affect prostate cancer cells or neovascular tissue in tumors. One of the prodrug is currently tested in clinical phase II.

    Original languageEnglish
    JournalSteroids
    Volume97
    Pages (from-to)2-7
    Number of pages6
    ISSN0039-128X
    DOIs
    Publication statusPublished - May 2015

    Fingerprint

    Dive into the research topics of 'Targeting thapsigargin towards tumors'. Together they form a unique fingerprint.

    Cite this